Catalyst Wire Dossier Catalyst Wire Dossier

YL201

· MediLink Therapeutics (Suzhou) Co., Ltd.
Drug timelines are a Plus or Pro feature.

11 regulatory and trial events tracked for YL201, covering 2025-02-10 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) [Phase 1]

See pricing